Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
OCS 
Oculis Holding AG Ordinary shares (OCS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/23/2025: OCS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $45.06
1 Year Target Price $45.06
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.54% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.18B USD | Price to earnings Ratio - | 1Y Target Price 45.06 |
Price to earnings Ratio - | 1Y Target Price 45.06 | ||
Volume (30-day avg) 7 | Beta 0.14 | 52 Weeks Range 14.00 - 23.08 | Updated Date 12/23/2025 |
52 Weeks Range 14.00 - 23.08 | Updated Date 12/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.71 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8352.26% |
Management Effectiveness
Return on Assets (TTM) -33.35% | Return on Equity (TTM) -92.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 997085258 | Price to Sales(TTM) 1487.19 |
Enterprise Value 997085258 | Price to Sales(TTM) 1487.19 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.47 | Shares Outstanding 57806909 | Shares Floating 39934746 |
Shares Outstanding 57806909 | Shares Floating 39934746 | ||
Percent Insiders 5.72 | Percent Institutions 39.45 |
Upturn AI SWOT
Oculis Holding AG Ordinary shares
Company Overview
History and Background
Oculis Holding AG is a clinical-stage biopharmaceutical company focused on developing innovative treatments for eye diseases. Founded in 2014, it has advanced its pipeline through key clinical trials and strategic partnerships, aiming to address unmet needs in ophthalmology.
Core Business Areas
- Ophthalmology Therapeutics: Development and commercialization of novel drug candidates for various eye conditions, including dry eye disease, uveitis, and diabetic macular edema.
Leadership and Structure
Oculis Holding AG is led by a management team with experience in pharmaceutical development and commercialization. The company operates under a typical corporate structure with distinct departments for research and development, clinical affairs, regulatory affairs, and business operations.
Top Products and Market Share
Key Offerings
- Product Name 1: OC16: A topical neurokinin-1 receptor antagonist for the treatment of dry eye disease. Competitors include Restasis, Xiidra, and topical corticosteroids.
- Product Name 2: OC102: A novel molecule targeting inflammation in the eye for conditions like uveitis. Competitors include corticosteroids and biologics like adalimumab.
Market Dynamics
Industry Overview
The ophthalmology market is a significant and growing segment of the pharmaceutical industry, driven by an aging global population, increasing prevalence of eye diseases, and advancements in treatment modalities. The market is characterized by intense competition, high R&D costs, and stringent regulatory requirements.
Positioning
Oculis Holding AG positions itself as an innovator in ophthalmology, focusing on novel mechanisms of action and targeted therapies. Its competitive advantages lie in its proprietary drug delivery technology and its pipeline of potential first-in-class or best-in-class treatments for underserved ophthalmic conditions.
Total Addressable Market (TAM)
The global market for ophthalmic drugs is substantial and projected to grow significantly. Oculis Holding AG is focused on specific segments within this TAM, such as dry eye disease, which represents billions of dollars in market value. The company's positioning is to capture a share of these high-value segments with its differentiated product candidates.
Upturn SWOT Analysis
Strengths
- Innovative pipeline with novel mechanisms of action.
- Proprietary drug delivery technology.
- Experienced management team in the biopharmaceutical sector.
- Focus on significant unmet needs in ophthalmology.
Weaknesses
- Clinical-stage company with no approved products yet.
- Reliance on successful clinical trial outcomes.
- Significant funding requirements for R&D and commercialization.
- Limited brand recognition in a competitive market.
Opportunities
- Growing demand for effective treatments for eye diseases.
- Potential for strategic partnerships and collaborations.
- Expansion into new therapeutic areas within ophthalmology.
- Emerging markets with increasing healthcare access.
Threats
- Clinical trial failures or delays.
- Intense competition from established and emerging players.
- Regulatory hurdles and pricing pressures.
- Patent expirations and generic competition for existing treatments.
Competitors and Market Share
Key Competitors
- Allergan (AbbVie) (AGN)
- Regeneron Pharmaceuticals (REGN)
- Novartis (NVS)
- Roche (RHHBY)
Competitive Landscape
Oculis Holding AG operates in a highly competitive landscape dominated by large pharmaceutical and biotechnology companies with established portfolios and significant R&D budgets. Its advantages lie in its focused approach on novel mechanisms and potentially differentiated therapies, but it faces challenges in matching the commercial reach and resources of its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Oculis Holding AG has been primarily in pipeline development and advancing its lead candidates through clinical stages. This includes securing funding, building its scientific team, and progressing through regulatory processes.
Future Projections: Future growth projections are contingent on the successful clinical development and regulatory approval of its product candidates, followed by market penetration. Analyst estimates would focus on potential peak sales of its lead products and the overall market opportunity.
Recent Initiatives: Recent initiatives likely include advancements in ongoing clinical trials, potential license agreements or partnerships, and efforts to secure additional funding to support late-stage development and commercialization planning.
Summary
Oculis Holding AG is a promising clinical-stage biopharmaceutical company in the ophthalmology sector. Its strengths lie in its innovative pipeline and focus on unmet needs, but it faces significant risks associated with clinical development and competition. Future success hinges on successful clinical trials, regulatory approvals, and effective market entry against established players.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company public filings (e.g., SEC filings if applicable)
- Industry reports on ophthalmology market
- Financial news and analysis websites
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The information provided is based on publicly available data and general industry knowledge. Investors should conduct their own due diligence before making any investment decisions. Market share data is illustrative and may not reflect precise current figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oculis Holding AG Ordinary shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-02 | CEO & Director Dr. Riad Sherif M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://oculis.com |
Full time employees 49 | Website https://oculis.com | ||
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.